How can we improve patients’ access to new drugs under uncertainties?: South Korea’s experience with risk sharing arrangements

Boram Lee  
Graduate School of Public Health, Seoul National University  
https://orcid.org/0000-0001-5117-1377

Eun-Young Bae  
Gyeongsang National University

SeungJin Bae  
Ewha Womans University College of Pharmacy

HyunJin Choi  
Health Insurance Review and Assessment Service

Kyung-Bok Son  
Ewha Womans University College of Pharmacy

Young-Sil Lee  
Seoul National University Graduate School of Public Health

Suhyun Jang  
Gachon University College of Pharmacy

Tae-Jin Lee  
Seoul National University Graduate School of Public Health  
https://orcid.org/0000-0003-2539-3579

Research article

Keywords: cost-effectiveness, drug reimbursement, economic evaluation, patients access, risk sharing arrangement, South Korea

DOI: https://doi.org/10.21203/rs.3.rs-63507/v1

License: ☕ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: New drugs including cancer drugs and orphan drugs are becoming increasingly more expensive. Risk sharing arrangements (RSAs) could manage the risk based on both financial impact and the health outcome of new drugs if reimbursed. To improve patients’ access to new drugs under uncertainties, many developed countries have adopted RSAs. In this study, we aimed to understand the effects of RSAs in South Korea on patients’ access.

Methods: We reviewed current status of RSA drugs in South Korea. The number of appraisals and time gap between market approval and reimbursement per RSA drug were considered to quantify improvement of patients’ access as they showed how rapidly decisions on reimbursement of RSA drugs were derived. Then, we applied a comparative analysis to determine whether the RSA drugs in South Korea were reimbursed in the UK, Italy, and Australia. Most data for this study were obtained from websites of the governmental department/agencies responsible for appraisal of drug reimbursement in each country. And literatures related to RSAs were investigated as well.

Results: The eligibility for Korean RSAs had two key components - drugs for cancer and rare diseases and not having other alternative treatments. As of the first half of 2019, there were 39 RSA drugs reimbursed in South Korea, the majority of which were financial-based schemes. Refund and expenditure cap were the representative types (89.7%). After introduction of RSAs, the time gap and number of appraisals were decreased. Based on the indications of RSA drugs, the level of drug coverage in South Korea was found lower than Italy, similar to the UK, and higher than Australia.

Conclusions: RSAs in South Korea significantly enhanced patients’ access to new drugs and led to the alleviation of patients’ out-of-pocket expenses. The drug coverage of South Korea had a level comparable to that of other countries. This study provides implications for countries that have a dual mission of containing pharmaceutical expenditure and improving access to new drugs.

Background

New drugs, especially cancer drugs and orphan drugs, are becoming increasingly more expensive. Unfortunately, however, a higher price does not always guarantee greater effectiveness. Nevertheless, most patients prefer early access to new drugs. However, payers and patients cannot easily afford them. This problem can be found in many countries, leaving health authorities with a challenging task of balancing between two issues – early access and cost containment.

Since the early 2000s, risk sharing arrangements (RSAs) have been introduced to manage the “risk” based on both financial impact and the health outcome of new drugs [1, 2]. Payers and manufacturers share the burden of these risks to achieve a common goal: expansion of coverage. There are three categories of risk sharing schemes: (1) performance-based schemes, which consider clinical efficacy, with the outcome of patients linked to price and/or coverage of drugs; (2) financial-based schemes, which are related to the cost of drugs, such as price discount, rebate, price-volume agreements, and
expenditure/utilization cap; and (3) evidence-generating schemes, which are implemented to collect more sufficient evidence in the real world.

Decisions of drug reimbursement may be deferred due to a lack of information, ultimately leading to uncertainties regarding these new drugs [3]. This deferment can be disappointing for patients who desire new drugs. However, the authorities must allocate healthcare funding over the entire population based on clinical efficacy and cost-effectiveness. Under this circumstance, RSAs can be a notable policy tool for satisfying different stakeholders. Patients receive timely access while payers (also called as insurers, governments, or purchasers) reduce a financial burden and an uncertainty of evidence. Further, pharmaceutical companies can improve market access and easily adhere to the global pricing strategy [4].

Over two-thirds of the Organization for Economic Co-operation and Development and European Union countries have been utilizing or had utilized RSAs by 2019 [5]. Goals, schemes, and implementations for risk sharing differ according to the background of each country. There are several other terms on RSAs—managed entry agreements, special pricing arrangements, patient access schemes, managed access schemes, and so on. Nonetheless, their initiatives begin at the same line – scarce resources in healthcare. Ferrario and Kanavos (2013) suggested three objectives for these arrangements: managing budgetary impact, purchasing cost-effective therapeutics, and monitoring utilization [6].

South Korea also introduced RSAs to improve patient’s access to new drugs in 2013. Since December 2006, South Korea has implemented a positive listing system for drug reimbursement, in which pharmaceutical companies should submit evidence of cost-effectiveness for most drugs. However, high-price drugs for cancer and rare diseases often miss these reimbursements due to failure to prove cost-effectiveness. As the number of these cases increased, calls from patients to improve the access to those drugs continued to increase, to which the Korean government responded by introducing RSAs.

The main purpose of this study is to describe the features and implications of RSAs in South Korea and review their effects on patients’ access to new drugs. Additionally, we aim to compare the levels of patients’ access to new drugs between South Korea and several developed countries – the UK, Australia and Italy. This may yield some implications for other countries struggling between increasing pharmaceutical expenditure and the need for early access.

**Risk sharing arrangements in South Korea**

In September 2013, the Ministry of Health and Welfare (MoHW) in South Korea officially announced the introduction of RSAs to help alleviate the financial burden associated with the treatment of patients with severe diseases and allow better access to new drugs. RSAs were restricted to the implementation of drugs that could be hardly accessed otherwise. To be eligible for RSAs, a drug should meet the following three criteria: (1) must be a cancer drug or orphan drug for rare diseases; (2) there should be neither alternative treatments nor equivalent therapeutic drugs available; and (3) drugs used to treat serious, life-threatening condition. Alternatively, a drug can be eligible if the Drug Reimbursement Evaluation
Committee (DREC) reaches an agreement based on the severity of the disease, social impacts, influence on public health, and other factors. [7]. The period of this contract can be up to four years; however, for an extension to be granted, a re-evaluation is necessary.

There are four stipulated types of RSAs in South Korea: 1) conditional treatment continuation and money back guarantee, a type that is based on individual patient’s response after treatment. If the response meets the predefined treatment goal, the drug continues to be reimbursed by the payer, the National Health Insurance Service (NHIS). Otherwise, the company should refund the full drug costs to the NHIS; 2) expenditure cap, which sets the total annual expenditure of the drug in advance. The company pays back an agreed rate of the exceeding amount to the NHIS; 3) a refund type where the company refunds a certain percentage of the nominal price of the drug to the NHIS; 4) utilization cap or fixed cost per patient, which designates the upper limit of utilization of the drug per patient. Further, the company covers the cost of the drug beyond pre-agreed utilization. Other ad hoc types of RSAs can also be suggested by the company [8].

Since the introduction of RSAs in 2013, the Korean government has allowed this agreement based on product alone but not indication. Accordingly, only one agreement was allowed for each RSA drug despite its indications being two or more. Since October 2016, however, adding new indications to the existing contract of RSA drugs has become possible. As a result, the new indication had to be appraised by the DREC, which can amend the terms of the contract through a negotiation between the NHIS and a pharmaceutical company for the remaining contract period. All RSA drugs should be monitored for their utilization at specific intervals. At the end of the period, re-evaluation of the eligibility for extension of the contract should be performed. If there is a therapeutic alternative to a specific RSA drug, the contract cannot be extended. If its generic is listed during the contract period, the contract must be immediately terminated.

Despite these approaches through RSAs to expand the coverage of the Korean national health insurance (NHI), some drugs are still not reimbursed by the NHIS. In the case of ultra-rare diseases, it appeared almost impossible to generate evidence for cost-effectiveness. In December 2014, the MoHW introduced an exemption of economic evaluation (EEE) policy and implemented it with very strict criteria. Only cancer drugs or orphan drugs could receive a waiver of economic evaluation when they satisfy three requirements: (1) the condition is so severe that patients’ lives are threatened and there is no alternative intervention; (2) the number of patients is too small to generate evidence; and (3) the drug is reimbursed in at least three of the following seven countries: the UK, Italy, France, Germany, Switzerland, the US, and Japan [9]. Moreover, since September 2016, every new drug introduced by the EEE policy should share its risk in the form of an expenditure cap.

**Risk sharing arrangements in the UK, Australia, and Italy**

National health service (NHS) England has patient access schemes (PAS) to manage the risk of uncertainty and cancer drugs fund (CDF) to provide patients with faster access to new cancer treatments [10, 11]. Tracing back to its origin in 2002, there was an agreement between the Department of Health
(DoH) and pharmaceutical companies on the long-term cost-effectiveness of multiple sclerosis patients [12]. In 2007, the DoH and the National Institute for Health and Care Excellence (NICE) proposed a legislation of PAS which was applied in the context of value-based pricing under a pharmaceutical price regulation scheme [13]. There are two broad categories in PAS: a simple discount scheme and a complex scheme [10]. The simple discount scheme involves discounting the price of a drug while complex schemes involves all other types including rebates, stock supplied at zero cost, dose capping and performance-based risk sharing. The patient access schemes liaison unit reviews the PAS proposals submitted by pharmaceutical companies, which are presented at the consultation with the NICE. To contain drug cost, simple discount was the most frequent type of PAS [14, 15]. In April 2011, the CDF was established, as a temporary measure until March 2016 [11], to provide early access to cancer drugs not recommended by the NICE. However, before long, the NHS faced financial pressure and CDF was completely amended in July 2016. As a key part of CDF, CDF-managed access agreement is considered to collect data. This contributes to the management of clinical uncertainties related to the NICE appraisal [16]. Thus, the current new CDF operates under population-level coverage with an evidence development (CED) scheme [5].

In 1998, the Department of Health of Australia reached an agreement with a pharmaceutical company to minimize the risks related to appropriateness and cost-effectiveness of drugs reimbursed by the Pharmaceutical Benefits Scheme (PBS) [17]; this served as the first agreement. The deeds of agreement was then introduced in 2003 to cover the two types of arrangements: special pricing arrangement (SPA) and risk sharing arrangement (RSA). SPA has a dual price — published price and real, confidential price. The refund by the companies should follow according to the difference between these two prices. RSA addresses various risks derived from the reimbursement of a new drug. Cost-effectiveness, overall cost to the PBS, overall health gain requiring data collection and monitoring, and overall utilization related to the number of patients are representative risks handled via RSA [18]. These two arrangements mainly manage financial-related risks and are sometimes used in combination schemes, refund with subsidization or expenditure cap [4]. Since 2011, the Australian PBS has operated managed entry schemes (MES) to share the risks associated with uncertainty for efficacy and help patients receive earlier access to drugs [19]. New drugs with high clinical needs are eligible for MES. Under MES, an initial price of the drug is established and evidence from clinical trials must be submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) within a specified timeframe. By reviewing resubmitted data, the PBAC can propose a final recommendation for the PBS listing and the drug price will be reset at this future time. Although not a form of risk sharing, the life saving drugs program (LSDP) has helped Australian patients access drugs for life threatening and rare diseases since 1995 [20].

Italian NHS (Servizio Sanitario Nazionale, SSN) named its risk sharing policy managed entry agreement (MEA) for cost containment and patients’ accessibility. MEA provides its application via two schemes—performance-based and financial-based [21]. In July 2006, the Agenzia Italiana del Farmaco (AIFA) agreed on its first MEA. Italian MEAs are classified into four types. Payment by result and risk sharing are classified as performance-based schemes while cost sharing and capping are classified as financial-based. If patients do not respond to treatment, risk sharing model proposes a discount to treatment cost.
However, under payment by result model, the pharmaceutical company should offer 100% payback. Cost sharing model discounts treatment cost of medication while capping forces the expenditure limit.

**Methods**

We described the current status and history of RSA drugs in South Korea including their indications, type of risk sharing, and changes of reimbursement condition. To understand its effect on patients’ access to drugs, we focused on how rapidly decisions on reimbursement of RSA drugs were derived, using two measures. One is the time gap between the date of market approval by the Ministry of Food and Drug Safety (MFDS) and the first date of reimbursement by the NHIS. The other is the number of appraisals per RSA drug completed by the DREC before it reaches a contract for RSA.

Subsequently, we sought to determine whether the RSA drugs in South Korea are reimbursed in other countries such as the UK, Italy, and Australia. Based on their indications, each RSA drug in South Korea was investigated to determine whether and how they are reimbursed – through conventional reimbursement, RSAs, or other special programs; this could help us to understand patients’ access to those drugs in South Korea. The UK (NHS England), Italy, and Australia were selected as they are very active at adopting RSAs and have either national health service or tax-funded universal health insurance. Likewise, South Korea has NHI that only has a single payer, the NHIS; it covers all Koreans as the same beneficiaries. In this context, circumstances surrounding decision making in drug reimbursement seem to be quite similar among these four countries. Furthermore, there are some advantages to obtaining official data among the selected countries.

For the Korean data, we searched the official governmental documents online. Official websites of Health Insurance Review and Assessment Service (HIRA) that operates the DREC, NHIS, MFDS, and MoHW were the main sources of the Korean data. We reviewed regulations for reimbursement, proceedings/minutes of the appraisal by the DREC, and a drug list of reimbursement by the NHIS [7–9, 22–25]. In addition, literatures related to RSAs in South Korea were investigated, such as peer-reviewed articles and nonconventional publications including government reports, press releases, and dissertations/theses. For the data from the UK, Italy, and Australia, websites for the governmental department/agencies responsible for appraisal of drug reimbursement in each country were included: NHS England and the NICE in the UK, AIFA in Italy, and the PBS in Australia. We reviewed the lists of PAS, CDF, and national tariff excluded drugs list for the UK data [10, 26–28]. AIFA discloses the reimbursement list for class H, class A drugs, and MEAs [29–31]. We performed a more comprehensive review for the Australian PBS data. To obtain information regarding MES and RSA, we examined every public summary documents that mentioned MES and financial management. We identified the outcomes for which the PBAC was only recommended while the rejected or deferred results were excluded [32]. The pharmaceutical schedules were checked for drugs subsidized under the PBS and other arrangements, especially SPA [33–35]. Our last update was performed in July 2019.

**Results**
Figure 1 shows the number of newly contracted RSA drugs in South Korea per year. As of the first half of 2019, 39 individual drugs were or had been reimbursed under RSAs. RSAs with EEE were applied to 18 drugs. In 2017, the largest number of drugs (i.e., 15 drugs) was reimbursed under RSAs. Over three quarters of the total were cancer drugs (30 drugs, 76.9%).

The current status and characteristics of the RSA drugs are described in Table 1. Further, these drugs were categorized according to their active or expired RSA contracts. Although the activation of 6 drugs was expired, they are still reimbursed. Financial-based schemes were most predominant in Korean RSAs, with one exception, clofarabine, the very first RSA drug under evidence-generating scheme. The company suggested CED type of risk sharing, where clofarabine was covered for all the relevant patients. The most common financial schemes were refund (17 drugs, 43.6%) and expenditure cap (23 drugs, 59.0%). All drugs under the expenditure cap were exempted from economic evaluation despite two having their arrangements settled before September 2016. Five drugs (nivolumab, pembrolizumab, cabozantinib, daratumumab, and nusinersen) had a combined scheme with refund and expenditure cap. Utilization cap, time cap, and discounted treatment initiation type of risk sharing also existed for each drug.
Table 1
List of RSA drugs in South Korea

| Brand name | Active substance | Type       | Start date (End date) | Note                                                                 |
|------------|------------------|------------|-----------------------|----------------------------------------------------------------------|
| Erbitux    | cetuximab        | refund     | 5-Mar-2014 (1-Jul-2018) | re-evaluation for RSA                                               |
| Xtandi     | enzalutamide     | refund     | 1-Nov-2014 (13-Feb-2019) | re-evaluation for RSA                                               |
| Soliris    | eculizumab       | refund     | 1-Oct-2015            | refund pilot program (1-Oct-2012), Essential drug                  |
| Caprelsa   | vandetanib       | expenditure cap | 1-Nov-2015 | Under EEE                                                           |
| Naglazyme  | galsulfase       | refund     | 1-Mar-2016 (1-Dec-2009) | refund pilot program (1-Dec-2009), Essential drug                  |
| Stivarga   | regorafenib      | refund     | 1-Jun-2016            |                                                                       |
| Vimizim    | elosulfase alfa  | expenditure cap | 1-Jun-2016 | Under EEE                                                           |
| Pomalyst   | pomalidomide     | refund     | 1-Jan-2017            |                                                                       |
| Defitelio  | defibrotide      | expenditure cap | 1-Jun-2017 | Under EEE                                                           |
| Perjeta    | pertuzumab       | time cap per patient | 1-Jun-2017 |                                                                       |

RSA, risk sharing arrangement; EEE, exemption of economic evaluation; CED, coverage with evidence development
| **Brand name** | **Active substance** | **Type** | **Start date** | **Note** |
|----------------|----------------------|----------|---------------|----------|
| Zelboraf       | vemurafenib          | expenditure cap | 1-Jul-2017     | Under EEE |
| Kadcyla        | trastuzumab emtansine | utilization cap | 3-Aug-2017     |          |
| Opdivo         | nivolumab            | refund + expenditure cap | 21-Aug-2017 |          |
| Keytruda       | pembrolizumab        | refund + expenditure cap | 21-Aug-2017 |          |
| Rafinlar       | dabrafenib           | expenditure cap | 1-Sep-2017    | Under EEE |
| Lynparza       | olaparib             | expenditure cap | 1-Oct-2017    | Under EEE |
| Meqsel         | trametinib           | expenditure cap | 1-Nov-2017    | Under EEE |
| Ibrance        | palbociclib          | refund    | 6-Nov-2017    |          |
| Tagrisso       | osimertinib          | discounted treatment initiation | 5-Dec-2017 |          |
| Tecentriq      | atezolizumab         | expenditure cap | 12-Jan-2018   | Under EEE |
| Sylvant        | siltuximab           | expenditure cap | 1-Feb-2018    | Under EEE |
| Kyprolis       | carfilzomib          | refund    | 5-Feb-2018    |          |

RSA, risk sharing arrangement; EEE, exemption of economic evaluation; CED, coverage with evidence development
| Brand name | Active substance | Type | Start date (End date) | Note |
|------------|------------------|------|-----------------------|------|
| Iclusig    | ponatinib        | expenditure cap | 1-Apr-2018 | Under EEE |
| Imbruvica  | ibrutinib        | expenditure cap | 1-Apr-2018 | Under EEE |
| Cyramza    | ramucirumab      | refund | 1-May-2018 |     |
| Blincyto   | blinatumomab     | expenditure cap | 1-Jul-2018 | Under EEE |
| Vyndaqel   | tafamidis        | expenditure cap | 1-Oct-2018 | Under EEE |
| Cabometyx  | cabozantinib     | refund + expenditure cap | 1-Feb-2019 |     |
| Praxbind   | idarucizumab     | expenditure cap | 1-Feb-2019 | Under EEE |
| Darzalex   | daratumumab      | refund + expenditure cap | 8-Apr-2019 |     |
| Spinraza   | nusinersen       | refund + expenditure cap | 8-Apr-2019 |     |

*Limited activation*

| Olita      | olmutinib        | expenditure cap | 15-Nov-2017 | Under EEE |
| Lartruvo   | olaratumab       | expenditure cap | 1-Dec-2018  | Under EEE |

*Expired activation*

RSA, risk sharing arrangement; EEE, exemption of economic evaluation; CED, coverage with evidence development
| Brand name | Active substance | Type         | Start date (End date) | Note                                                                                       |
|------------|------------------|--------------|-----------------------|--------------------------------------------------------------------------------------------|
| Evoltra    | clofarabine      | CED          | 11-Dec-2013 (1-Dec-2018) | the first RSA drug, conventional reimbursement after re-evaluation                          |
| Revlimid   | lenalidomide     | refund       | 5-Mar-2014 (1-Dec-2017) | conventional reimbursement due to generic                                                  |
| Xalkori    | crizotinib       | refund       | 1-May-2015 (1-May-2019) | conventional reimbursement due to alternative drugs after re-evaluation                   |
| Pirespa    | pirfenidone      | refund       | 3-Oct-2015 (1-Nov-2017) | conventional reimbursement due to generic                                                  |
| Diterin    | sapropterin      | expenditure cap | 1-Nov-2017 (8-May-2019) | Under EEE, conventional reimbursement due to generic                                      |
| Alecensa   | alectinib        | expenditure cap | 1-Oct-2017 (1-Dec-2018) | Under EEE, conventional reimbursement due to alternative drugs after expansion of the indication |

RSA, risk sharing arrangement; EEE, exemption of economic evaluation; CED, coverage with evidence development
Eculizumab and galsulfase were first reimbursed by the refund pilot program, which was launched in August 2009. This also enabled the NHIS to receive “pay-back” from pharmaceutical companies with a certain fraction of the drug price. Although it was initially intended to last only one year, several extensions took place until RSAs were introduced. Following the termination of the pilot program, the DREC appraised their eligibility for RSAs.

Two drugs had limited activation (olmutinib and olaratumab). The MFDS had granted them conditional approval; however, their phase III clinical trials failed and the manufacturers abandoned their development. Therefore, these two drugs are only available for current patients who have been treated with them (i.e., dispensing of these medications for new patients is not allowed).

Four drugs were re-evaluated before the termination of their four-year activation period: cetuximab, enzalutamide, clofarabine, and crizotinib. The first two were successful at obtaining re-agreements with the same type. Although the other two drugs were unsuccessful, the DREC confirmed their reimbursement through conventional appraisal – the clinical efficacy of clofarabine was proven and alternative agents to crizotinib were revealed. Accordingly, these two drugs are no longer under RSAs; however, they are reimbursed in a manner similar to non-RSA drugs. Meanwhile, the activation of three drugs (pirfenidone, lenalidomide, and sapropterin) was terminated due to the listing of generics before the end of the contracted period. One drug (alectinib) was converted to conventional reimbursement from RSAs because it added a new indication for which there were alternative drugs.

Table 2 shows that access to RSA drug has accelerated in South Korea. On average, approximately 850 days had passed for all RSA drugs before the start of reimbursement following market approval. They were divided into three groups according to the MFDS approval year based on time of policy introduction – 2013 for RSAs and 2015 for EEE.
Table 2
Days between approval and reimbursement and the counts of appraisal for reimbursement of RSA drugs in South Korea

|                               | Total    | RSA only | RSA with EEE |
|-------------------------------|----------|----------|--------------|
| All drugs                     | N        | 39       | 21           | 18           |
| days between approval         |          |          |              |              |
| and reimbursement             |          |          |              |              |
| average number of appraisals‡ |          | 1.92     | 2.24         | 1.56         |
| Market approval               | N        | 12       | 10           | 2            |
| by MFDS                       |          |          |              |              |
| before 2014                   |          | 1167.4   | 1131.4       | 1347.5       |
| days between approval         |          |          |              |              |
| and reimbursement             |          |          |              |              |
| average number of appraisals‡ |          | 2.83     | 2.70         | 3.50         |
| Market approval               | N        | 14       | 5            | 9            |
| by MFDS                       |          |          |              |              |
| in 2014–2015                  |          | 923.7    | 1010.0       | 875.8        |
| days between approval         |          |          |              |              |
| and reimbursement             |          |          |              |              |
| average number of appraisals‡ |          | 1.64     | 1.80         | 1.56         |
| Market approval               | N        | 13       | 6            | 7            |
| by MFDS                       |          |          |              |              |
| after 2015†                   |          | 475.9    | 465.0        | 485.3        |
| days between approval         |          |          |              |              |
| and reimbursement             |          |          |              |              |
| average number of appraisals‡ |          | 1.38     | 1.83         | 1.00         |

† until the first half of 2019; ‡ not including deferred appraisal; MFDS, Ministry of Food and Drug Safety

The activation date of eculizumab and galsulfase was applied with the refund pilot program (October 1, 2012 and December 1, 2009, respectively).

A third of RSA drugs were approved after 2016. The time gap between market approval and reimbursement was remarkably decreased. Drugs approved before RSAs took 1,167 days for reimbursement. After the introduction of RSAs, 924 days were taken, a decrease of eight months. Finally, it was reduced by almost 60% — 476 days after the introduction of EEE. A similar trend was found for the average number of appraisals by the DREC for each drug (approximately 2.8 number of times for drugs approved before 2014 and 1.4 for drugs approved after 2016).
Kim analyzed the impact of some policies on drug reimbursement, including RSAs and EEE [36]. After the introduction of a positive listing system, 430 new drugs were appraised by the DREC between January 2007 and May 2018. Among them, cancer drugs and orphan drugs for rare diseases accounted for 30.2% (130 drugs). The policies of RSAs and EEE dramatically increased the rate of DREC approval for cancer and orphan drugs. It was only 40.8% between 2007 and 2013; but increased to 50.0% after the introduction of RSAs; and doubled after the introduction of EEE (82.0%). In the case of other new drugs, these percentages were 68.4%, 79.3%, and 80.8%, respectively.

We carried out a comparative analysis of the risk sharing and other policies on patients’ access in South Korea, NHS England, Italian SSN, and Australian PBS. Based on our findings, there were considerable overlaps between these three countries and South Korea. Similar to South Korea, financial-based schemes were a common type of risk sharing in the UK and Australia. Table 3 shows types of risk sharing and their number of applied indications. There were 64 indications for 39 Korean RSA drugs. In the case of Korean NHI, 52 indications (81.3%) were reimbursed. The remaining 12 indications were not reimbursed or approved in South Korea. In the UK, 38 indications (59.4%) were reimbursed. Among them, 33 indications were under PAS – 27 for simple discount and 5 for complex scheme. Further, there was a combination of PAS and CDF (daratumumab). Fourteen indications (21.9%) were subsidized by CDF. In Italy, 59 indications (92.2%) were reimbursed and nine of them had MEAs – five for outcome-based and four for financial-based. A total of 39 indications (60.9%) were reimbursed by the Australian PBS. Mixed schemes were very common in Australia. MES was only applied for 4 indications in combination with other access schemes. 32 indications managed their financial risks by RSAs and/or SPAs. Trametinib was the only drug that applied those three arrangements all together. Finally, three drugs were listed in the LSDP. The supplementary table shows more details about this comparison.
Table 3
Comparison of Korean RSA drugs with the UK, Italy, and Australia

|                | No. of indications | % of reimbursed |
|----------------|-------------------|-----------------|
| **Total**      | 64                | 100.0           |
| **South Korea**|                   |                 |
| RSA refund     | 11                |                 |
| expenditure cap| 22                |                 |
| refund + expenditure cap | 7          |                 |
| others         | 3                 |                 |
| conventional reimbursement | 9        |                 |
| **sub total**  | 52                | 81.3            |
| not reimbursed | 11                |                 |
| not approved   | 1                 |                 |
| **UK**         |                   |                 |
| PAS simple discount | 27        |                 |
| complex scheme | 5                 |                 |
| PAS + CAA      | 1                 |                 |
| conventional reimbursement | 5        |                 |
| **sub total**  | 38                | 59.4            |
| CDF            | 14                | 21.9            |
| not reimbursed | 12                |                 |
| **Italy**      |                   |                 |
| MEA financial-based | 4         |                 |
| outcome-based  | 5                 |                 |
| conventional reimbursement | 50       |                 |
| **sub total**  | 59                | 92.2            |
| not reimbursed | 5                 |                 |
| **Australia**  |                   |                 |
| MES            | 0                 |                 |
| financial RSA  | 2                 |                 |
| SPA            | 4                 |                 |

RSA, risk sharing arrangement; PAS, patients access scheme; CAA, CDF (cancer drug fund) managed access agreement; CDF, cancer drug fund; MEA, managed entry agreement; MES, managed entry scheme; SPA, special pricing arrangements; LSDP, life-saving drugs program
| No. of indications | % of reimbursed |
|--------------------|-----------------|
| financial RSA + SPA | 26              |
| MES + SPA          | 1               |
| MES + financial RSA | 2               |
| MES + financial RSA + SPA | 1           |
| conventional reimbursement | 3        |
| sub total          | 39              | 60.9          |
| LSDP               | 3               | 4.7           |
| not reimbursed      | 22              |

RSA, risk sharing arrangement; PAS, patients access scheme; CAA, CDF (cancer drug fund) managed access agreement; CDF, cancer drug fund; MEA, managed entry agreement; MES, managed entry scheme; SPA, special pricing arrangements; LSDP, life-saving drugs program

Discussion

There are some uncertainties regarding pharmaceutical reimbursement based on clinical evidence and cost-effectiveness. RSAs are mechanisms that share these risks between stakeholders. In 2013, the Korean government introduced RSAs as part of the NHI coverage expansion plan for cancer drugs and orphan drugs. Additionally, there is the EEE policy for the waiver of economic evaluation introduced in 2015. In South Korea, 39 drugs took advantage of RSAs – 31 had effective activation, 2 were only limited to pre-treated patients, and the activation of 6 was expired; however, they were still reimbursed in a conventional manner. Almost all were arranged by a financial-based scheme. Refund was identified as the majority type and all expenditure caps were applied for drugs under EEE. The time gap between market approval by the MFDS and reimbursement by the NHIS for RSA drugs was decreased. Additionally, a decrease in the number of DREC appraisal per RSA drug was observed. This helped to shorten the time gap and consequently alleviate patients' financial burden by virtue of subsidy by NHI. To compare 39 RSA drugs in South Korea and their various indications, we examined the drug lists in the UK, Italy, and Australia. The types of risk sharing varied across countries and the indications under RSAs differed according to each jurisdiction despite being from the same drug. In Italy, more than 90% of indications were included; this was followed by South Korea (81.3%), Australia (60.9%), and the UK (51.6%). But including CDF, the proportion of indications being subsidized by government is almost three-fourths in the UK. This means CDF plays a significant role in patients' access to drugs in the UK. In any case, it can be said that Korean patients' access to these new drugs is not limited relative to these countries.
In most countries, health authorities have attempted to find a balance between cost containment and the expansion of coverage. Notably, the improvement of patients’ early access to new drugs through RSAs has been highlighted [2–6, 15, 37–39]. Similarly, we found some significant results from the experiences of South Korea. Before RSAs were introduced, new drugs that had uncertainties regarding their cost-effectiveness tended to be rejected or were assigned a pending status by the DREC. Once a decision was deferred, it was inevitable to prepare for the next meeting. Pharmaceutical companies were asked to modify their rejected strategies (e.g., drug price and model of economic evaluation) and re-submit their applications for reimbursement. Accordingly, the number of DREC’s appraisals and the time to receiving a reimbursement were increased inevitably. In fact, these drugs may have not been reimbursed if RSAs had not been introduced. The criteria of being eligible for RSAs could help the DREC to arrive at a decision more quickly. Consequently, less than two rounds of appraisal meetings were required to make a positive decision after 2013. Therefore, RSAs and EEE in South Korea could be evaluated as a contribution to patients’ access to medicine.

RSA also led to the alleviation of patients’ out-of-pocket expenses for new drugs. According to the HIRA’s report, patients’ out-of-pocket expenses were annually reduced by KRW 130 billion (USD 150.7 million using purchasing power parity in 2016) based on a scenario analysis for the early-adopted 11 RSA drugs [40]. All stakeholders, including patient group, policymakers, healthcare professionals, non-governmental organizations, and pharmaceutical companies, appreciated the worth of Korean RSAs because of their access to medicine [40].

The coverage level of Korean RSAs was not found to be insufficient compared to that of the UK, Australia, and Italy. However, the Korean RSAs only apply to cancer and rare diseases while in the other three countries, there is no restriction for diseases. Nevertheless, cancer drugs account for most of the RSA drugs in these countries. This is because they are lifesaving and very expensive [5, 41]. There seems to be more focus on financial-based schemes in all four countries. However, this tendency could be easily found in other countries. The development and management of RSAs result in administrational and bureaucratic burden. Further, transaction time and the costs for executing RSAs to all stakeholders are burdensome with performance-based schemes being more difficult than financial-based schemes [2, 5, 41]. To adopt performance-based schemes, payers should be prepared to measure appropriate health outcomes. The paucity of guidelines on performance-based schemes might encourage the development of the financial-based scheme. In terms of complexity, preference for financial-based schemes is somewhat of a natural consequence. However, there are differences in the implementation of RSAs between countries just as the names of policy differ between countries. These diversities are derived from the circumstances of each country, including public demands, health system, eligibility criteria for risk sharing, and evaluation framework for reimbursement.

In South Korea, RSAs provide a non-conventional framework for covering new drugs under NHI. The criterion, “no alternative treatment,” plays a very important role at the initial evaluation and the re-evaluation of RSA drugs. The RSA contracts for five drugs were terminated because they did not satisfy the criterion; three were faced with their generics during their contract period while the other two had
therapeutically equivalent drugs available at the time of re-evaluation. “No alternative treatment” is a very important criterion that is used by the DREC during their decision-making regarding reimbursement.

In South Korea, the issue of diseases that are eligible for RSAs was raised. Specific protocols have been derived to implement RSAs for cancer and orphan drugs alone. Recently, the MoHW added detailed requirements for the regulation of RSAs with drugs for other diseases; (1) drugs without alternative therapeutic treatments, (2) drugs for severe incurable diseases, (3) drugs that offer clinically significant improvement to patients’ quality of life, and (4) drugs approved as breakthrough therapy designation (BTD) or priority medicines (PRIME) by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Drugs that satisfy the four aforementioned conditions could be reimbursed with RSAs. Since 2020, dupilumab for moderate-to-severe atopic dermatitis has been reimbursed with RSAs. In fact, it is the first non-cancer, non-orphan drug reimbursed with RSAs in South Korea. Despite the extension of the therapeutic area, “no alternative” is still emphasized as a strict rule for evaluation.

Similar to other policies, RSAs have both advantages and disadvantages. Although policy-makers implementing RSAs could lessen the uncertainty in cost-effectiveness and clinical benefit, there remains some budgetary matters (i.e., as many patients get early access, a greater budget pressure would ensue). A lack of transparency also serves as another issue [2, 5, 37, 42]. In most cases, the detailed condition of agreements and the results from evaluating patients’ health outcome remain confidential. Refund is a simple and widespread type of risk sharing; however, it is often criticized because of its dual price system. Regarding the performance-based scheme, if data were unveiled, additional efforts to generate clinical evidence could be avoided. Although pharmaceutical companies may not be comfortable with data release, it is imperative that they bear in mind that patients and payers have been willing to share their information to aid in the generation of evidence for the new drugs.

This study had some limitations. First, we could only access and collect data published online in Korean or English. Because almost all conditions surrounding the agreements were confidential in South Korea, we could not estimate the actual expenditure of NHI nor the reduction of patients’ out-of-pocket payments due to RSAs. Further, confidentiality has been observed in the other three countries. In Australia, a final decision on the PBAC’s recommendation was not disclosed. Thus, of the 39 RSA drugs, we only examined the PBAC’s outcomes for MEAs/RSAs of the drugs listed in the pharmaceutical schedules.

**Conclusion**

This study demonstrated that RSAs in South Korea significantly improved patients’ access to new drugs. Further, it revealed that drug coverage of Korean NHI had a level comparable to that of other countries. Our findings could thus serve as reference points for countries that have a dual mission of containing pharmaceutical expenditure and improving access to new drugs.

**List Of Abbreviations**
AIFA: Agenzia Italiana del Farmaco
CDF: cancer drugs fund
DoH: Department of Health
DREC: Drug Reimbursement Evaluation Committee
EEE: exemption of economic evaluation
HIRA: Health Insurance Review and Assessment Service
LSDP: life saving drugs program
MEA: managed entry agreement
MES: managed entry schemes
MFDS: Ministry of Food and Drug Safety
MoHW: Ministry of Health and Welfare
NHI: national health insurance
NHIS: National Health Insurance Service
NHS: national health service
NICE: National Institute for Health and Care Excellence
PAS: patient access schemes
PBAC: Pharmaceutical Benefits Advisory Committee
PBS: Pharmaceutical Benefits Scheme
RSA: risk sharing arrangement
SPA: special pricing arrangement

Declarations

Ethics approval and consent to participate: Not applicable.
Consent for publication: Not applicable.
Availability of data and materials: The datasets generated and/or analyzed during the current study are available as follows

Korean data:
Drugs Reimbursement Evaluation Committee final recommendation in the HIRA website, http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014040000.[22]
List of reimbursed drugs and prices in the HIRA website, http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000.[23]
Information of drug approval in the MFDS website. https://nedrug.mfds.go.kr/searchDrug.[24]

the UK data:
NHS England Drugs List in NHS England website, https://www.england.nhs.uk/wp-content/uploads/2019/04/nhs-england-drugs-list-v14.1.pdf.[26]
PAS list in the NICE website, https://www.nice.org.uk/Media/Default/About/what-we-do/PASLU/NICE-recommended-technologies-that-include-a-commercial-arrangement.xlsx.[27]
CDF list in NHS England website, https://www.england.nhs.uk/wp-content/uploads/2017/04/national-cdf-list-v1.135.pdf.[28]

Italian data:
Drug list on class A and class H in AIFA website, http://www.agenziafarmaco.gov.it/content/elenco-medicinali-di-fascia-e-h.[29]
MEA list in AIFA website, http://www.agenziafarmaco.gov.it/content/comunicazioni-managed-entry-agreements-mea.[30]

Australian data:
General Pharmaceutical Schedule in the PBS website,
https://www.pbs.gov.au/publication/schedule/2019/06/2019-06-01-general-schedule-volume-1.pdf.[33]
Pharmaceutical Schedule - Section 100 Schedule in the PBS website,
https://www.pbs.gov.au/publication/schedule/2019/07/2019-07-01-section100-volume-2.pdf.[34]
Pharmaceutical Schedule - Efficient Funding of Chemotherapy in the PBS website,
https://www.pbs.gov.au/publication/schedule/2019/07/2019-07-01-efc.pdf.[35]
List of LSDP in the PBS website, https://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria.[20]

Competing interests: The authors declare that they have no competing interests.

Funding: There is no specific funding for this study.

Authors’ contributions: E-Y B, SB, and T-J L all contributed to the design and conception of the study. BL analyzed and interpreted the data, and was a major contributor in writing the manuscript. K-B S, Y-S L, HC, and SJ primarily completed data collection. All authors read and approved the final manuscript.
Acknowledgements: Not applicable.

References

1. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9.

2. Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–19.

3. Kanavos P, Ferrario A, Tafuri G, Siviero P. Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. Glob Policy. 2017;8:84–92.

4. Tuffaha HW, Scuffham PA. The Australian Managed Entry Scheme: Are We Getting it Right? Pharmacoeconomics. 2018;36(5):555–65.

5. 10.1787/6e5e4c0f-en

   Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward. OECD Health Working Papers, No. 115. Paris: OECD Publishing; 2019. doi:10.1787/6e5e4c0f-en.

6. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet; 2013.

7. Health Insurance Review and Assessment Service (HIRA). Detailed evaluation criteria for drugs subject to negotiation including new drugs. 2016.

8. National Health Insurance Service (NHIS). Detailed operation guidelines for risk-sharing drug pricing negotiation. 2016.

9. Health Insurance Review and Assessment Service (HIRA). Regulation for evaluation criteria and procedures for reimbursement eligibility of drugs. 2018.

10. National Institute for Health and Care Excellence (NICE). Patient access schemes liaison unit. https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit/list-of-technologies-with-approved-patient-access-schemes. Accessed 2 July 2019.

11. NHS England. Cancer Drugs Fund. https://www.england.nhs.uk/cancer/cdf/. Accessed 2 July 2019.

12. Spoors J. Patient access schemes in the new NHS. British Journal of Healthcare Management. 2012;18(8):412–8.

13. Espín J, Rovira J, García L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. Brussels: EMiNet; 2011.

14. Carlson JJ, Chen S, Garrison LP. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Pharmacoeconomics. 2017;35(10):1063–72.
15. Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Front Pharmacol. 2017;8:171.

16. National Institute for Health and Care Excellence (NICE). Cancer Drugs Fund. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/cancer-drugs-fund. Accessed 2 July 2019.

17. The Pharmaceutical Benefits Scheme (PBS). Guidelines for Deeds of Agreement. http://www.pbs.gov.au/info/industry/listing(elements/deeds-agreement/. Accessed 1 July 2019.

18. The Pharmaceutical Benefits Scheme (PBS). Background - Deeds of Agreement http://www.pbs.gov.au/info/industry/listing(elements/deeds-agreement/b-background. Accessed 1 July 2019.

19. The Pharmaceutical Benefits Scheme (PBS). Framework For Introduction Of Managed Entry Scheme For Submissions to PBAC. http://www.pbs.gov.au/info/publication/factsheets/shared/framework-for-introduction-of-managed-entry-scheme-for-PBAC-submissions. Accessed 1 July 2019.

20. The Pharmaceutical Benefits Scheme (PBS). Life Saving Drugs Program https://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria. Accessed 1 July 2019.

21. Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–3.

22. Health Insurance Review and Assessment Service (HIRA). Drugs Reimbursement Evaluation Committee final recommendation. http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014040000. Accessed 2 July 2019.

23. Health Insurance Review and Assessment Service (HIRA). List of reimbursed drugs and prices. 2019, 7. http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000. Accessed 2 July 2019.

24. Ministry of Food and Drug Safety (MFDS). Search for drug product information. https://nedrug.mfds.go.kr/searchDrug. Accessed 2 July 2019.

25. Ministry of Health and Welfare (MoHW). Press Release. http://www.mohw.go.kr/react/al/sal0301ls.jsp?PAR_MENU_ID=04&MENU_ID=0403. Accessed 2 July 2019.

26. NHS England. NHS England Drugs List, version 14.1. 2019. https://www.england.nhs.uk/wp-content/uploads/2019/04/nhs-england-drugs-list-v14.1.pdf. Accessed 2 July 2019.

27. National Institute for Health and Care Excellence (NICE). Recommended technologies that include a commercial arrangement. https://www.nice.org.uk/Media/Default/About/what-we-do/PASLU/NICE-recommended-technologies-that-include-a-commercial-arrangement.xlsx. Accessed 2 July 2019.

28. NHS England. National Cancer Drugs Fund List, version 1.135. 2019. https://www.england.nhs.uk/wp-content/uploads/2017/04/national-cdf-list-v1.135.pdf. Accessed 2 July 2019.

29. Agenzia Italiana del Farmaco (AIFA). Elenco Medicinali di fascia A e H. Dec 2018. http://www.agenziafarmaco.gov.it/content/elenco-medicinali-di-fascia-e-h. Accessed 5 July 2019.
30. Agenzia Italiana del Farmaco (AIFA). Comunicazioni Managed Entry Agreements (MEA).  
http://www.agenziafarmaco.gov.it/content/comunicazioni-managed-entry-agreements-mea. 
Accessed 5 July 2019.

31. Agenzia Italiana del Farmaco (AIFA). Registri Farmaci sottoposti a monitoraggio.  
http://www.agenziafarmaco.gov.it/content/registri-farmaci-sottoposti-monitoraggio. Accessed 5 
July 2019.

32. The Pharmaceutical Benefits Scheme (PBS). Public Summary Documents.  
http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd. Accessed 1 July 2019.

33. Department of Health. General Pharmaceutical Schedule. Canberra: Australian Government; 2019. 
https://www.pbs.gov.au/publication/schedule/2019/06/2019-06-01-general-schedule-volume-1.pdf. Accessed 1 July 2019.

34. Department of Health. Section 100 – Items Available under Special Arrangement. Canberra: Australian Government; 2019. 
https://www.pbs.gov.au/publication/schedule/2019/07/2019-07-01-section100-volume-2.pdf. Accessed 1 July 2019.

35. Department of Health. Efficient Funding of Chemotherapy. Canberra: Australian Government; 2019.  
https://www.pbs.gov.au/publication/schedule/2019/07/2019-07-01-efc.pdf. Accessed 1 July 2019.

36. Kim T-k. Analysis of Impacts of the supplementary schemes on the drug reimbursement decision- 
making under the Positive List System [master's thesis]. Seoul: Seoul National University; 2018.

37. Gonçalves FR, Santos S, Silva C, Sousa G. Risk-sharing agreements, present and future. 
Ecancermedicalscience. 2018;12:823.

38. Bouvy JC, Sapede C, Garner S. Managed Entry Agreements for Pharmaceuticals in the Context of 
Adaptive Pathways in Europe. Front Pharmacol. 2018;9:280.

39. Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health Policy.  
2014;117(3):345–52.

40. Lee T-J, Bae E-Y, Bae SJ, Son K-B, Yang DW, LEE B, et al. Risk sharing arrangements and post 
management policy. Wonju: Health Insurance Review and Service (HIRA); 2016.

41. Castro HE, Malpica-Llanos T, Musila R, Konduri N, Amaris A, Sullivan J, et al. Sharing knowledge for 
policy action in low-and middle-income countries: A literature review of managed entry agreements. 
Medicine Access @ Point of Care. 2019. doi:10.1177/2399202619834246.

42. Rotar AM, Preda A, Löblová O, Benkovic V, Zawodnik S, Gulacsi L, et al. Rationalizing the introduction 
and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern 
European countries. Health Policy. 2018;122(3):230–6.

Figures
Figure 1

Number of newly contracted RSA drugs per year. †First half of the year RSA, risk sharing arrangement; EEE, exemption of economic evaluation

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplement0814.docx